Insulet initiates voluntary correction for 7M Omnipod units due to insulin under-delivery risk.
Insulet Corporation announced a voluntary medical device correction for approximately 7 million Omnipod pods across multiple product lines due to a manufacturing defect causing potential insulin under-delivery, with 24 serious adverse events reported globally including hospitaliz
View filing at SEC.gov →